File photo shows a staff member displays samples of the COVID-19 inactivated vaccine at Sinovac Biotech Ltd., in Beijing. (Xinhua File/Zhang Yuwei)
A phase 2 trial of a COVID-19 vaccine candidate in China has found that the vaccine is safe and induces an immune response, according to a new study published Monday in medical journal The Lancet.
版權及免責聲明：凡本網所屬版權作品，轉載時須獲得授權并注明來源“粵港澳頭條”，違者本網將保留追究其相關法律責任的權力。凡轉載文章，不代表本網觀點和立場。
宏福苑五級火｜海底撈捐贈400萬元 為受災居民發(fā)放快餐食物
